AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
- Article
- Abstract
- The hypothetical basis for the benefits of MAO-B inhibition in Parkinson's disease.
- Clinical benefits of (-)-deprenyl.
- (-)-Deprenyl can increase neuronal survival in vivo and in vitro without inhibiting MAO-B.
- Apoptosis may be involved in neurodegeneration.
- Genes and proteins that promote or retard apoptosis.
- Evidence that mitochondria contribute to the initiation of apoptosis and that (-)-deprenyl alters apoptosis through a mitochondrial mechanism.
- (-)-Deprenyl alters the expression of genes that influence mitochondrial viability.
- Do the selective changes in gene expression explain the capacity of (-)-deprenyl to maintain mitochondrial membrane potential and reduce neuronal apoptosis?
- Do the actions of (-)-deprenyl on gene expression contribute to the benefits reported for (-)-deprenyl treatment in human neurodegenerative diseases?
- REFERENCES
- Figures & Data
- Info & Disclosures
Hemiplegic Migraine Associated With PRRT2 Variations A Clinical and Genetic Study
Dr. Robert Shapiro and Dr. Amynah Pradhan